Scarica l'app Stockscreener
701.85
0.90%
-6.40
Dopo l'orario di chiusura:
706.33
4.48
+0.64%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$708.25
Aprire:
$710.2
Volume 24 ore:
1.70M
Relative Volume:
2.10
Capitalizzazione di mercato:
$77.13B
Reddito:
$13.85B
Utile/perdita netta:
$4.65B
Rapporto P/E:
20.02
EPS:
35.06
Flusso di cassa netto:
$3.32B
1 W Prestazione:
-4.03%
1M Prestazione:
-5.58%
6M Prestazione:
-32.80%
1 anno Prestazione:
-16.62%
Intervallo 1D:
$700.83
$717.61
Intervallo di 1 settimana:
$693.00
$745.00
Portata 52W:
$693.00
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Regeneron advances anticoagulant antibody program - The Pharma Letter
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Principal Financial Group Inc. - MarketBeat
REGNRegeneron Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible - GlobeNewswire
Regeneron Will Move Two Factor XI Agents Into Phase III - Citeline News & Insights
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron reports positive results for two anti-coagulant drugs - Seeking Alpha
Regeneron says study data support big bet on new blood thinners - BioPharma Dive
Cutaneous Squamous Cell Carcinoma Market Set to Grow - openPR
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results - The Manila Times
Regeneron To Advance Two Factor Xi Antibodies Into A Broad Phase 3 Program - XM
Regeneron posts Phase 3 win for Eylea HD in retinal vein occlusion - MSN
Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month LowHere's Why - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study - Yahoo Finance
Broader Eylea HD label on the cards after Phase III win - The Pharma Letter
Atopic Dermatitis: A Crowded Field With Room To Grow - Citeline News & Insights
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by Canaccord Genuity Group - MarketBeat
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Regeneron to Present at J.P. Morgan Healthcare Conference 2025: Strategic Updates Expected - StockTitan
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease StudyRegeneron Pharmaceuticals (NASDAQ:REGN) - Benzinga
Regeneron, Bayer Build Retinal Vein Occlusion Case for Eylea as Biosimilar Pressure Mounts - BioSpace
Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Hold Rating from Analysts at Canaccord Genuity Group - MarketBeat
EYLEA HD achieves comparable vision gains with fewer doses - Investing.com
Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
Canaccord Genuity Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Hold Recommendation - MSN
Regeneron, Allele Settle Covid Cocktail Patent Infringement Suit - Bloomberg Law
Allele, Regeneron Settle COVID Treatment Patent Suit - Law360
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year - The Manila Times
Regeneron settles patent lawsuit over protein for testing COVID-19 treatments - Reuters.com
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Galderma’s Nemluvio Brings New Mechanism To Atopic Dermatitis - Citeline
Global EYLEA Drug Market: With CAGR of 7.2% by 20242031 Market - openPR
Lord Abbett & CO. LLC Sells 22,151 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Unloaded Rep. Jonathan L. Jackson - MarketBeat
Regeneron's SWOT analysis: eylea franchise faces challenges as stock navigates pipeline potential - Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week LowTime to Sell? - MarketBeat
Oddo BHF Asset Management Sas Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Wilmington Savings Fund Society FSB Raises Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt? - Simply Wall St
Regeneron stock touches 52-week low at $735 amid market shifts - Investing.com Australia
Regeneron Down 15.5% Year to Date: How to Play the Stock? - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Reduced by Franklin Resources Inc. - MarketBeat
Teachers Retirement System of The State of Kentucky Sells 7,517 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Enters Oversold Territory (REGN) - Nasdaq
Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma - PharmaVoice
Regeneron Fights Sandoz Eylea Patent-Misconduct Claims (Correct) - Bloomberg Tax
Blankinship & Foster LLC Buys New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Pine Valley Investments Ltd Liability Co Has $5.58 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Regeneron Pharmaceuticals Inc Azioni (REGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McCourt Marion | EVP Commercial |
Nov 01 '24 |
Sale |
844.61 |
1,000 |
844,610 |
12,931 |
0.16%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):